TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24433231

Group type: EXPERIMENTAL
Intervention: I Can Cope (4 sessions: learning about cancer; understanding cancer treatments; relieving cancer pain; keeping well in mind and body)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Wellness intervention (4 sessions: humor, meditation, relaxation, and music therapy)
Number of subjects: 140
Study: 23185761

Group type: EXPERIMENTAL
Intervention: Youdujing (YDJ) external lotion and YDJ cream
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Youdujing (YDJ) treatment
Number of subjects: 70
Study: 20473630

Group type: EXPERIMENTAL
Intervention: Ribonuclease-enriched lactoferrin (R-ELF) supplementation (2 × 125 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (calcium supplement only)
Number of subjects: 38
Study: 17495194

Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16135905

Group type: EXPERIMENTAL
Intervention: Community-level intervention
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Skills training workshops
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Education-only delayed control intervention
Number of subjects: 1172
Study: 11753129

Group type: EXPERIMENTAL
Intervention: Transurethral vaporization of the prostate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative finasteride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bladder infusion prior to catheter removal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol‐glycine in assessment of the absorption of irrigation fluid
Number of subjects: 0
Study: 11069268

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (matched normal-control subjects)
Number of subjects: 20
Study: 8839904

Group type: EXPERIMENTAL
Intervention: Tecogalan sodium (dosage levels: 125, 185, 240, 300, 390, 445, and 500 mg/m2) administered via single i.v. infusion every three weeks for 1 to 24 hours.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tecogalan sodium at the recommended phase II dose of 390 mg/m2 over 24 hours.
Number of subjects: 33
Study: 1602944

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (93% of total caloric intake as carbohydrate) after glycogen-depletion protocol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (23% of total caloric intake as carbohydrate) after glycogen-depletion protocol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Recorded ad libitum dietary consumption
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition (ad libitum diet)
Number of subjects: 14
Study: 6386932

Group type: EXPERIMENTAL
Intervention: Oral amrinone (113 +/- 33 mg three times daily)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Oral amrinone
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Oral amrinone and Placebo
Number of subjects: 173
Study: 31279306

Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific regimen not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy (in PENELOPE validation cohort)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab-chemotherapy (in AURELIA validation cohort)
Number of subjects: 0
Study: 29228160

Group type: EXPERIMENTAL
Intervention: Incentive plus usual care (n=5398 mother-infant dyads)
Number of subjects: 10010

Group type: COMPARATOR
Intervention: Usual care alone (n=4612 mother-infant dyads)
Number of subjects: 10010

Group type: EXPERIMENTAL
Intervention: Incentive plus usual care
Number of subjects: 10010

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 10010
Study: 26717304

Group type: EXPERIMENTAL
Intervention: DTC print ads with disease information
Number of subjects: 4064

Group type: COMPARATOR
Intervention: DTC print ads without disease information
Number of subjects: 4064
Study: 24818986

Group type: EXPERIMENTAL
Intervention: Medical websites
Number of subjects: 52

Group type: COMPARATOR
Intervention: General health and wellness control websites
Number of subjects: 52
Study: 22472523

Group type: EXPERIMENTAL
Intervention: Enhanced motivational interviewing (MI)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Brief advice (BA)
Number of subjects: 162
Study: 20305926

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study: 17985505

Group type: EXPERIMENTAL
Intervention: Walking an extra 30 minutes per day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no walking advice)
Number of subjects: 19
Study: 16306520

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg three times daily)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 182
Study: 11263599

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 8943

Group type: COMPARATOR
Intervention: Hirudin
Number of subjects: 8943

Group type: COMPARATOR
Intervention: No (re)MI
Number of subjects: 8943
Study: 9268808

Group type: EXPERIMENTAL
Intervention: English-speaking group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spanish-speaking group
Number of subjects: 0
Study: 8331205

Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate immediate-release (CT) tablets (2 x 20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adinazolam sustained-release (SR) tablets (2 x 30 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3570035

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cimetidine 400 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 7
Study: 2598862

Group type: EXPERIMENTAL
Intervention: Bone lid method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative procedure
Number of subjects: 60
Study: 31544802

Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation (NR) for 9±2 months with nutritional counselling and oral nutritional supplementation (n = 51)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Weight gain >7g/d during follow-up (n = 14)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Weight gain <7g/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group A (28 children improved BMI-SDS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Group B (23 children did not improve BMI-SDS)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Children with lower Ht-SDS before NR
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Linear growth velocity after NR
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 102
Study: 28363880

Group type: EXPERIMENTAL
Intervention: Web-based CPD program on providing oral hygiene care to stroke patients using TPB
Number of subjects: 547

Group type: COMPARATOR
Intervention: Web-based CPD program not specific to oral hygiene
Number of subjects: 547
Study: 26497942

Group type: EXPERIMENTAL
Intervention: Detailed informed consent process in neonatal research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical investigations on parental perspectives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large randomized controlled multicenter trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current funding and regulation of research
Number of subjects: 0
Study: 23182947

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 50
Study: 21709083

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg vs 600 mg
Number of subjects: 40
Study: 18249500

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 22982
Study: 16854197

Group type: EXPERIMENTAL
Intervention: Orthopedic Plate (OP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no OP)
Number of subjects: 0
Study: 15809819

Group type: EXPERIMENTAL
Intervention: Usual care plus nesiritide
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual care plus placebo
Number of subjects: 900
Study: 11179831

Group type: EXPERIMENTAL
Intervention: Variant MPO genotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wild-type MPO genotype
Number of subjects: 0
Study: 9024742

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8298540

Group type: EXPERIMENTAL
Intervention: Prescriptive psychotherapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Exploratory psychotherapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Prescriptive therapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Exploratory therapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 220
Study: 3552841

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) treatment
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 433
Study: 31010364

Group type: EXPERIMENTAL
Intervention: Muscular body build with muscle-encouraging messages
Number of subjects: 508

Group type: COMPARATOR
Intervention: Muscular body build with muscle-discouraging messages
Number of subjects: 508

Group type: COMPARATOR
Intervention: Average body build
Number of subjects: 508

Group type: COMPARATOR
Intervention: Overweight body build
Number of subjects: 508
Study: 28342632

Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor (90mg loading dose, then 90mg daily)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Standard-dose ticagrelor (180mg loading dose, then 90mg twice daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Clopidogrel (300mg loading dose, then 75mg daily)
Number of subjects: 52
Study: 25620535

Group type: EXPERIMENTAL
Intervention: Etifoxine 150 mg/day for 28 days
Number of subjects: 202

Group type: COMPARATOR
Intervention: Alprazolam 1.5 mg/day for 28 days
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Etifoxine
Number of subjects: 202

Group type: COMPARATOR
Intervention: Alprazolam
Number of subjects: 202
Study: 23421900

Group type: EXPERIMENTAL
Intervention: Inhaler training (verbal training, demonstration movie, and leaflet)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no inhaler training)
Number of subjects: 69
Study: 21375356

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 72
Study: 19067864

Group type: EXPERIMENTAL
Intervention: Corticosteroids (from twice daily to one application every other day) combined with the studied cream (twice daily)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Studied cream (twice daily)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Corticosteroids alone (once or twice daily)
Number of subjects: 86
Study: 16598851

Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 9
Study: 14681620

Group type: EXPERIMENTAL
Intervention: External jugular vein (EJV) patch
Number of subjects: 160

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) patch
Number of subjects: 160
Study: 11404143

Group type: EXPERIMENTAL
Intervention: hFABP
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CKMB
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TnI
Number of subjects: 35
Study: 9241289

Group type: EXPERIMENTAL
Intervention: Prediction model using maternal age, height, weight at delivery, nulliparity, history of cesarean delivery, and need for induction of labor.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prediction model with additional variable of need for labor augmentation.
Number of subjects: 0
Study: 8304709

Group type: EXPERIMENTAL
Intervention: recombinant interleukin‐2 (rIL‐2)
Number of subjects: 12
Study: 3584272

Group type: EXPERIMENTAL
Intervention: Oros drug delivery system (10/170 oxprenolol)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Slow Trasicor 160 mg orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rectal administration of pre‐equilibrated Oros systems
Number of subjects: 8
Study: 30807594

Group type: EXPERIMENTAL
Intervention: AAQ II Malay version
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 101
Study: 27910245

Group type: EXPERIMENTAL
Intervention: Solid-state sensors in seated position
Number of subjects: 78

Group type: COMPARATOR
Intervention: Solid-state sensors in lateral position
Number of subjects: 78

Group type: COMPARATOR
Intervention: Water-perfused sensors in lateral position
Number of subjects: 78
Study: 25430065

Group type: EXPERIMENTAL
Intervention: Intrinsic cognitive load manipulation (varying number of diagnoses learned in one instruction session)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extraneous cognitive load manipulation (providing single or multiple examples of diagnoses during instruction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Germane cognitive load manipulation (employing mixed or blocked sequences of diagnostic examples)
Number of subjects: 0
Study: 23591255

Group type: EXPERIMENTAL
Intervention: Continuous-combined estradiol 1 mg/drospirenone 2 mg (E2D)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21990176

Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg, 3 times per day, orally
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 18496952

Group type: EXPERIMENTAL
Intervention: Emergency bypass during clipping procedure (group I)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Emergency bypass for therapy refractory vasospasm (group II)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Planned bypass surgery (group III)
Number of subjects: 46
Study: 16803941

Group type: EXPERIMENTAL
Intervention: Examination without stirrups
Number of subjects: 197

Group type: COMPARATOR
Intervention: Examination with stirrups
Number of subjects: 197
Study: 12652173

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone loading for 24 hours
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10912543

Group type: EXPERIMENTAL
Intervention: Deflazacort (0.30+/‐0.03 mg/kg per day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Methylprednisone (0.20+/‐0.03)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Methylprednisone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 8793024

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Concentric exercise
Number of subjects: 10
Study: 1643923

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6228459

Group type: EXPERIMENTAL
Intervention: 3 micrograms heat-inactivated HBsAg vaccine
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: 27 micrograms heat-inactivated HBsAg vaccine
Number of subjects: 698
Study: 31866529

Group type: EXPERIMENTAL
Intervention: Increased frequency of sensor use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Management (PLGM) system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 0
Study: 31376515

Group type: EXPERIMENTAL
Intervention: Artemisia afra extracts and compounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 0
Study: 27888737

Group type: EXPERIMENTAL
Intervention: Dyadic sibling-focused intervention
Number of subjects: 328
Study: 26332605

Group type: EXPERIMENTAL
Intervention: VRC01 intravenous (i.v.) infusion at 20 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VRC01 intravenous (i.v.) infusion at 40 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VRC01 subcutaneous (s.c.) delivery at 5 mg/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo s.c. given twice, 28 days apart
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VRC01 (all doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VRC01 (5-40 mg/kg i.v. range)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VRC01
Number of subjects: 28
Study: 22855005

Group type: EXPERIMENTAL
Intervention: MnCOSA
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 21097899

Group type: EXPERIMENTAL
Intervention: LVEF quartiles 23-28%
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: LVEF quartiles 17-22%
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: LVEF quartiles < 17%
Number of subjects: 2008
Study: 19127261

Group type: EXPERIMENTAL
Intervention: WBRT+topotecan (RCT; 0.4 mg m(‐2) day(‐1) x 20)
Number of subjects: 96

Group type: COMPARATOR
Intervention: WBRT (20 x 2 Gy)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: WBRT+topotecan (RCT)
Number of subjects: 96
Study: 18379495

Group type: EXPERIMENTAL
Intervention: Paravertebral blockades (PVB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Antianginal and metabolic therapy
Number of subjects: 67
Study: 15475832

Group type: EXPERIMENTAL
Intervention: 3 g oleic capsaicin-containing patches
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11534472

Group type: EXPERIMENTAL
Intervention: Western diet composed of 45% fat, 40% carbohydrate and 15% protein by energy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Standard breakfast of constant composition
Number of subjects: 8
Study: 9769871

Group type: EXPERIMENTAL
Intervention: 2 nucleoside analogues
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2 nucleoside analogues and a protease inhibitor
Number of subjects: 30
Study: 8933253

Group type: EXPERIMENTAL
Intervention: Health education intervention provided to parents in the post-natal period.
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (no health education intervention).
Number of subjects: 169
Study: 2390434

Group type: EXPERIMENTAL
Intervention: 250 mg mefloquine base weekly
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 125 mg mefloquine base weekly
Number of subjects: 20
Study: 6786115

Group type: EXPERIMENTAL
Intervention: Telephone counseling (N: 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clinic counseling (N: 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (N: 20)
Number of subjects: 40
Study: 31845008

Group type: EXPERIMENTAL
Intervention: Group-based educational workshop
Number of subjects: 156
Study: 31268730

Group type: EXPERIMENTAL
Intervention: Individual educational session with a promotora
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group educational session with a promotora
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 100
Study: 27630110

Group type: EXPERIMENTAL
Intervention: Healthy Caregivers‐Healthy Children (HC2) intervention
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Injury prevention/safety intervention (Control)
Number of subjects: 1211
Study: 27258249

Group type: EXPERIMENTAL
Intervention: 150 mg FeLf (iron-lactoferrin complex) per day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 23791561

Group type: EXPERIMENTAL
Intervention: Neck manual therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Pragmatic, evidence-based treatment to the shoulder (control group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 68
Study: 22995971

Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation with INR of 2 to 3
Number of subjects: 4060
Study: 20973464

Group type: EXPERIMENTAL
Intervention: Newcastle disease vaccination program for chickens
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control villages (no vaccination)
Number of subjects: 498
Study: 18005833

Group type: EXPERIMENTAL
Intervention: Skeletal anchorage (n = 10)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Orthognathic surgery (LeFort I osteotomy combined with mandibular osteotomy) (n = 13)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 23
Study: 16047062

Group type: EXPERIMENTAL
Intervention: Screening program including free and total prostate specific antigen (PSA) and digital rectal examination (DRE)
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (TRUS) and ultrasound guided biopsy of the prostate
Number of subjects: 1213
Study: 11851660

Group type: EXPERIMENTAL
Intervention: Laparoscopic abdominal rectopexy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open abdominal rectopexy
Number of subjects: 40
Study: 9550207

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vaginal weight cones
Number of subjects: 60
Study: 7874873

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin with responsive thromboplastin
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose warfarin with high international sensitivity index thromboplastin
Number of subjects: 0
Study: 2965227

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 52

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Diuretics and vasodilating agents (added where blood pressure was insufficiently controlled)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall treatment (beta-blockers and methyldopa)
Number of subjects: 52
Study: 31955619

Group type: EXPERIMENTAL
Intervention: TNF‐α inhibitor (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Steroid (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lidocaine-only (Group C)
Number of subjects: 90